Related Experiment Video
Updated: Jul 19, 2026
10:00
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Interferon after 10 years in patients with multiple sclerosis.
C Pozzilli1, L Prosperini, E Sbardella
1Department of Neurological Sciences, La Sapienza University, Viale dell'Università 30, I-00185 Rome, Italy. carlo.pozzilli@uniroma1.it
Summary
Interferon beta (IFNbeta) therapy is a primary treatment for multiple sclerosis (MS), but long-term data is limited. Neutralizing antibodies can reduce its effectiveness, impacting patient compliance and treatment benefits.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic neurological disease impacting young adults.
- Disease-modifying therapies, including Interferon beta (IFNbeta), have improved MS management.
- Current IFNbeta treatments present challenges in long-term efficacy, administration, and patient adherence.
Purpose of the Study:
- To review the long-term safety, tolerability, and efficacy of Interferon beta (IFNbeta) in multiple sclerosis (MS).
- To address the limitations in current knowledge regarding the long-term effects of IFNbeta therapy.
- To discuss the impact of neutralising antibodies (NAbs) on IFNbeta treatment outcomes in MS.
Main Methods:
- Review of clinical trial data and post-marketing studies on Interferon beta (IFNbeta) in multiple sclerosis (MS).
- Analysis of factors affecting long-term treatment outcomes, including patient compliance and antibody development.
- Evaluation of the current role of IFNbeta as a first-line treatment in MS.
Main Results:
- Interferon beta (IFNbeta) has established safety and tolerability profiles in multiple sclerosis (MS) from short-term studies.
- Limited data exists on the long-term efficacy and safety of IFNbeta therapy.
- Development of neutralising antibodies (NAbs) against IFNbeta can diminish treatment benefits.
Conclusions:
- Interferon beta (IFNbeta) remains a first-choice treatment for multiple sclerosis (MS) despite limitations.
- Further research is needed to understand the long-term impact of IFNbeta therapy and strategies to mitigate NAb development.
- Improving administration and patient compliance are crucial for optimizing IFNbeta treatment in MS.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...